{"id":"W2103254744","doi":"10.3109/10428194.2012.660631","title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Cytarabine; Medicine; Myeloid leukemia; Neutropenia; Refractory (planetary science); Fms-Like Tyrosine Kinase 3; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Chemotherapy; Chemistry; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001537633,0.001484419,0.002684975,0.001348231,0.0003576131,0.000114979,0.0008601104,0.001390721,0.0003309196],"category_scores_gemma":[0.0007010315,0.001140119,0.0004619259,0.002143834,0.001059476,0.001367544,0.000524185,0.0008321214,0.0001650634],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02262229,"about_ca_system_score_gemma":0.01427664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001514795,"about_ca_topic_score_gemma":0.00008945221,"domain_scores_codex":[0.9904514,0.00049941,0.00238342,0.001660247,0.002277387,0.002728146],"domain_scores_gemma":[0.9936379,0.0008915998,0.001024897,0.00211002,0.0006089053,0.001726729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6312938,0.009109416,0.05880365,0.001111115,0.001973098,0.001269698,0.003995566,0.00002095391,0.007034099,0.0005306343,0.009105941,0.2757521],"study_design_scores_gemma":[0.7484466,0.01664509,0.1882542,0.0009965277,0.001174177,0.0006574193,0.0007196905,0.0009504569,0.008514349,0.00005419032,0.03168878,0.001898469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990001,0.0008461534,0.00005590432,0.0001236294,0.0007537439,0.003529177,0.0001906216,0.0003035959,0.004196156],"genre_scores_gemma":[0.9894493,0.001172131,0.002425104,0.0009265448,0.001006569,0.0003893354,0.0005829339,0.0003777629,0.0036703],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2738536,"threshold_uncertainty_score":0.9999057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0167819574737144,"score_gpt":0.2891959538203783,"score_spread":0.2724139963466639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}